Nadofaragene firadenovec- vncg (ADSTILADRIN) is A recommended treatment option: In the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)* and the AUA/ SUO Guidelines1 By …

Mar 27, 2026 · The active substance of Adstiladrin is nadofaragene firadenovec, an antineoplastic cell and gene therapy (ATC code: L01XL10). Nadofaragene firadenovec is a non-replicating, …

Nadofaragene firadenovec, sold under the brand name Adstiladrin, is a gene therapy for the treatment of bladder cancer. [1][3][4] It is a non-replicating (cannot multiply in human cells) adenoviral vector …

Apr 1, 2026 · Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer. Includes …

ADSTILADRIN® is the first and only FDA-approved gene therapy for treating adult patients with high-risk BCG-unresponsive NMIBC. See Important Safety Info.

Oct 10, 2025 · STN: BLA 125700 Proper Name: nadofaragene firadenovec-vncg Tradename: ADSTILADRIN Manufacturer: Ferring Pharmaceuticals A/S Indication: ADSTILADRIN is indicated for …

Mar 24, 2026 · ADSTILADRIN ® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical non-replicating gene-therapy for the treatment of adult patients with high-risk Bacillus …

Mar 24, 2026 · ADSTILADRIN (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy for intravesical instillation. It is a recombinant adenovirus serotype 5 vector …

Jun 19, 2023 · Adstiladrin (Nadofaragene Firadenovec-vncg Suspension, for Intravesical Use) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications …

Jan 16, 2024 · About ADSTILADRIN ADSTILADRIN® (nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical gene-therapy for the treatment of adult patients with high-risk …